These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 19343327

  • 1. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
    Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R.
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Aug; 380(2):169-77. PubMed ID: 19343327
    [Abstract] [Full Text] [Related]

  • 2. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
    Elens L, Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, Mourad M, Kuypers DR, Haufroid V, van Gelder T, van Schaik RH.
    Ther Drug Monit; 2014 Feb; 36(1):71-9. PubMed ID: 24061445
    [Abstract] [Full Text] [Related]

  • 3. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
    Elens L, van Schaik RH, Panin N, de Meyer M, Wallemacq P, Lison D, Mourad M, Haufroid V.
    Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
    [Abstract] [Full Text] [Related]

  • 4. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
    Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, Åsberg A, Christensen H.
    Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
    [Abstract] [Full Text] [Related]

  • 5. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, Suarez-Kurtz G.
    Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
    [Abstract] [Full Text] [Related]

  • 6. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
    Żochowska D, Wyzgał J, Pączek L.
    Ann Transplant; 2012 Sep; 17(3):36-44. PubMed ID: 23018254
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T.
    Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
    Yildirim E, Şahin G, Kaltuş Z, Çolak E.
    Clin Lab; 2019 Nov 01; 65(11):. PubMed ID: 31710427
    [Abstract] [Full Text] [Related]

  • 14. Switching Immunosuppression From Cyclosporine to Tacrolimus in Kidney Transplant Recipients Based on CYP3A5 Genotyping.
    Wang X, Yang Y, Liu Z, Xiao C, Gao L, Zhang W, Zhang W, Wang Z.
    Ther Drug Monit; 2019 Feb 01; 41(1):97-101. PubMed ID: 30520827
    [Abstract] [Full Text] [Related]

  • 15. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
    Liu LS, Li J, Chen XT, Zhang HX, Fu Q, Wang HY, Xiong YY, Liu S, Liu XM, Li JL, Huang M, Wang CX.
    Int J Clin Pract Suppl; 2015 May 01; (183):43-52. PubMed ID: 26177348
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?
    Singh R, Srivastava A, Kapoor R, Mittal RD.
    J Clin Pharmacol; 2011 Apr 01; 51(4):603-15. PubMed ID: 20571034
    [Abstract] [Full Text] [Related]

  • 18. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K, Kolsi A, Kerkeni E, Ben Fredj N, Chaabane A, Monastiri K, Boughattas N.
    Pharmacogenomics; 2015 Dec 01; 16(18):2045-54. PubMed ID: 26615671
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
    Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK.
    Eur J Clin Pharmacol; 2008 Nov 01; 64(11):1069-84. PubMed ID: 18636247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.